Business Description
Soligenix Inc
NAICS : 325412
SIC : 2834
ISIN : US8342233074
Description
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.47 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.37 | |||||
| Debt-to-EBITDA | -0.28 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -31.51 | |||||
| Beneish M-Score | -4.74 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 53.4 | |||||
| 3-Year EPS without NRI Growth Rate | 56.9 | |||||
| 3-Year FCF Growth Rate | 43.7 | |||||
| 3-Year Book Growth Rate | -49 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 24.92 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.28 | |||||
| Quick Ratio | 2.28 | |||||
| Cash Ratio | 2.17 | |||||
| Days Sales Outstanding | 308.85 | |||||
| Days Payable | 1412.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -71.9 | |||||
| Shareholder Yield % | -15.57 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -191.45 | |||||
| Operating Margin % | -6637.61 | |||||
| Net Margin % | -6067.52 | |||||
| FCF Margin % | -6773.15 | |||||
| ROE % | -209.89 | |||||
| ROA % | -71.71 | |||||
| ROIC % | -256.74 | |||||
| ROC (Joel Greenblatt) % | -3783.06 | |||||
| ROCE % | -201.52 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 18.82 | |||||
| PB Ratio | 1.3 | |||||
| Price-to-Tangible-Book | 1.29 | |||||
| EV-to-EBIT | -0.1 | |||||
| EV-to-EBITDA | -0.1 | |||||
| EV-to-Revenue | 6.58 | |||||
| EV-to-Forward-Revenue | 2.17 | |||||
| EV-to-FCF | -0.1 | |||||
| Price-to-Median-PS-Value | 3.98 | |||||
| Price-to-Net-Current-Asset-Value | 1.34 | |||||
| Price-to-Net-Cash | 1.45 | |||||
| Earnings Yield (Greenblatt) % | -1000 | |||||
| FCF Yield % | -95.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Soligenix Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.108 | ||
| EPS (TTM) (€) | -0.147 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 6.012 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 6.012 - 6.012 | ||
| Shares Outstanding (Mil) | 10.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Soligenix Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Soligenix Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Soligenix Inc Frequently Asked Questions
What is Soligenix Inc(STU:DOA)'s stock price today?
The current price of STU:DOA is €6.01. The 52 week high of STU:DOA is €6.01 and 52 week low is €6.01.
When is next earnings date of Soligenix Inc(STU:DOA)?
The next earnings date of Soligenix Inc(STU:DOA) is 2025-02-08 Est..
Does Soligenix Inc(STU:DOA) pay dividends? If so, how much?
Soligenix Inc(STU:DOA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers